A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor
- PMID:17478612
- DOI: 10.1124/mol.106.033746
A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor
Abstract
THRX-160209 is a potent antagonist at the M(2) muscarinic acetylcholine (ACh) receptor subtype that was designed using a multivalent strategy, simultaneously targeting the orthosteric site and a nearby site known to bind allosteric ligands. In this report, we describe three characteristics of THRX-160209 binding that are consistent with a multivalent interaction: 1) an apparent affinity of the multivalent ligand for the M2 receptor subtype (apparent pK(I) = 9.51 +/- 0.22) that was several orders of magnitude greater than its two monovalent components (apparent pK(I) values < 6.0), 2) specificity of THRX-160209 for the M2 receptor subtype compared with the closely related M4 (apparent pK(I) = 8.78 +/- 0.24) and M1, M3, and M5 receptors (apparent pK(I) values <or= 8.0), and 3) acceleration (>10-fold) of the dissociation rate of tritium-labeled THRX-160209 from M2 receptors by competing monovalent ligands that are known to interact with either the orthosteric site (e.g., atropine) or a well characterized allosteric site (e.g., obidoxime) on the receptor. In complementary kinetic studies assessing allosteric modulation of the receptor, unlabeled THRX-160209 retarded dissociation of [3H]N-methyl scopolamine (NMS). The effects of THRX-160209 on retardation of [3H]NMS dissociation were competitively inhibited by obidoxime, suggesting that obidoxime and THRX-160209 bind to an overlapping region coincident with other typical muscarinic allosteric agents, such as 3-methyl-5-[7-[4-[(4S)-4-methyl-1,3-oxazolidin-2-yl]phenoxy]heptyl]-1,2-oxazole (W84) and gallamine. Taken together, these data are consistent with the hypothesis that THRX-160209 binds in a multivalent manner to the M2 receptor, simultaneously occupying the orthosteric site and a spatially distinct allosteric site.
Similar articles
- THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner.Steinfeld T, Hughes AD, Klein U, Smith JA, Mammen M.Steinfeld T, et al.Mol Pharmacol. 2011 Mar;79(3):389-99. doi: 10.1124/mol.110.069120. Epub 2010 Dec 7.Mol Pharmacol. 2011.PMID:21139051
- Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.Tränkle C, Weyand O, Voigtländer U, Mynett A, Lazareno S, Birdsall NJ, Mohr K.Tränkle C, et al.Mol Pharmacol. 2003 Jul;64(1):180-90. doi: 10.1124/mol.64.1.180.Mol Pharmacol. 2003.PMID:12815174
- Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors.Tränkle C, Mohr K.Tränkle C, et al.Mol Pharmacol. 1997 Apr;51(4):674-82. doi: 10.1124/mol.51.4.674.Mol Pharmacol. 1997.PMID:9106634
- Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Bryant A, Hiu S, Kunonga PT, Gajjar K, Craig D, Vale L, Winter-Roach BA, Elattar A, Naik R.Bryant A, et al.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.Cochrane Database Syst Rev. 2022.PMID:36161421Free PMC article.Review.
- Exploring conceptual and theoretical frameworks for nurse practitioner education: a scoping review protocol.Wilson R, Godfrey CM, Sears K, Medves J, Ross-White A, Lambert N.Wilson R, et al.JBI Database System Rev Implement Rep. 2015 Oct;13(10):146-55. doi: 10.11124/jbisrir-2015-2150.JBI Database System Rev Implement Rep. 2015.PMID:26571290
Cited by
- Discovery of a Novel Class of Negative Allosteric Modulator of the Dopamine D2 Receptor Through Fragmentation of a Bitopic Ligand.Mistry SN, Shonberg J, Draper-Joyce CJ, Klein Herenbrink C, Michino M, Shi L, Christopoulos A, Capuano B, Scammells PJ, Lane JR.Mistry SN, et al.J Med Chem. 2015 Sep 10;58(17):6819-43. doi: 10.1021/acs.jmedchem.5b00585. Epub 2015 Aug 28.J Med Chem. 2015.PMID:26258690Free PMC article.
- Emerging paradigms in GPCR allostery: implications for drug discovery.Wootten D, Christopoulos A, Sexton PM.Wootten D, et al.Nat Rev Drug Discov. 2013 Aug;12(8):630-44. doi: 10.1038/nrd4052.Nat Rev Drug Discov. 2013.PMID:23903222Review.
- Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease.Volpato D, Holzgrabe U.Volpato D, et al.Molecules. 2018 Dec 7;23(12):3230. doi: 10.3390/molecules23123230.Molecules. 2018.PMID:30544533Free PMC article.Review.
- Design, synthesis and biological evaluation of novel orthosteric-allosteric ligands of the cannabinoid receptor type 2 (CB2R).Ferrisi R, Gado F, Polini B, Ricardi C, Mohamed KA, Stevenson LA, Ortore G, Rapposelli S, Saccomanni G, Pertwee RG, Laprairie RB, Manera C, Chiellini G.Ferrisi R, et al.Front Chem. 2022 Sep 27;10:984069. doi: 10.3389/fchem.2022.984069. eCollection 2022.Front Chem. 2022.PMID:36238097Free PMC article.
- Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets.Scarr E.Scarr E.CNS Neurosci Ther. 2012 May;18(5):369-79. doi: 10.1111/j.1755-5949.2011.00249.x. Epub 2011 Feb 26.CNS Neurosci Ther. 2012.PMID:22070219Free PMC article.Review.
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases